Director/PDMR Shareholding
Renalytix plc announced that Joel Jung, interim Chief Financial Officer, purchased 500 American Depositary Shares (ADS) at $2.85 per ADS on February 11, 2026. This transaction increases his total interest to 333,855 Ordinary Shares, representing 0.07% of the company's issued share capital. The purchase of these ADSs, each comprising 50 Ordinary Shares, was conducted on the OTC New York market.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 13 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk assessment in chronic diabetic kidney disease, announces that on 11 February 2026 Joel Jung, interim Chief Financial Officer, bought a further 500 American Depositary Shares (ADS) at a price of US$2.85 per ADS. ADS consist of 50 Ordinary Shares of £0.0025 each.
Following this transaction, Joel Jung is interested in 333,855 Ordinary Shares representing 0.07% of the issued share capital of the Company.
| a) | Name | J oel Jung |
| 2 | Reason for the notification | |
| a) | Position/status | interim Chief Financial Officer |
| b) | Initial notification /Amendment | Initial Notification |
| a) | Name | Renalytix plc |
| b) | LEI | 213800NTOH3FK3WER551 |
| a) | Description of the financial instrument, type of instrument | American Depository Shares (ADS) which consist of 50 Ordinary Shares at £0.0025 each |
| Identification code | GB00BYWL4Y04 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| $2.85 | 500 | |
| d) | Aggregated information | |
| - Aggregated volume | 500 | |
| - Price | $1,425 | |
| e) | Date of the transaction | 11 February 2026 |
| f) | Place of the transaction | OTC New York |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.